Nonoxinol 9


Concise Prescribing Info
Indications/Uses
Spermicidal contraception.
Dosage/Direction for Use
Adult : Vag As gel: To be used in conjunction with barrier methods of contraception such as diaphragms or caps. Apply approx 2 cm strips on each side of the diaphragm or fill 1/3 of the cap. Apply extra gel if coitus takes place 3 hours or more after insertion of diaphragms or cap. Allow the diaphragm to remain undisturbed for at least 6 hours after coitus. Apply more cream or other spermicides prior to any subsequent coitus within this period, without removing the diaphragm/cap. Use a vaginal applicator for inserting more gel. Alternatively, as gel/foam: Insert 1 applicatorful into the vaginal prior to intercourse. As film: Insert 1 film as far into the vagina as possible against the cervix. As sponge: Insert 1 sponge deep into the vagina. Wait 6 hours after the last intercourse before removing the sponge. Refer to individual product guideline for detailed application instructions.
Dosage Details
Vaginal
Spermicidal contraception
Adult: As gel: To be used in conjunction with barrier methods of contraception such as diaphragms or caps. Apply approx 2 cm strips on each side of the diaphragm or fill 1/3 of the cap. Apply extra gel if coitus takes place 3 hours or more after insertion of diaphragms or cap. Allow the diaphragm to remain undisturbed for at least 6 hours after coitus. Apply more cream or other spermicides prior to any subsequent coitus within this period, without removing the diaphragm/cap. Use a vaginal applicator for inserting more gel. Alternatively, as gel/foam: Insert 1 applicatorful into the vaginal prior to intercourse. As film: Insert 1 film as far into the vagina as possible against the cervix. As sponge: Insert 1 sponge deep into the vagina. Wait 6 hours after the last intercourse before removing the sponge. Refer to individual product guideline for detailed application instructions.
Contraindications
Hypersensitivity to nonoxinol 9. Absence of vaginal sensation (e.g. paraplegics, quadriplegics).
Special Precautions
Patient using contraceptive devices. Pregnancy and lactation. Nonoxinol 9 does not protect against HIV infection or other STDs.
Adverse Reactions
Significant: Toxic shock syndrome, vaginal irritation (e.g. rash, itching, burning), genital lesion.
Renal and urinary disorders: Urethral irritation or pain; bacteriuria, urinary tract infection.
Reproductive system and breast disorders: Penile pain, discomfort, burning, itching, dryness, rash, and redness.
Action
Description: Nonoxinol 9 is a nonionic surfactant used as a spermicide. It acts by damaging the sperm cell membrane, causing an increased membrane permeability with subsequent loss of cell components and reduced motility and function.
Synonym: nonoxynol 9
Chemical Structure

Chemical Structure Image
Nonoxinol

Source: National Center for Biotechnology Information (2020). PubChem Compound Summary for CID 72385, Nonoxynol-9. Retrieved September 24, 2020 from https://pubchem.ncbi.nlm.nih.gov/compound/Nonoxynol-9.

Storage
Store at 25°C.
References
Anon. Nonoxinols. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 16/09/2020.

Buckingham R (ed). Nonoxynol 9. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/09/2020.

Gygel Contraceptive Jelly (Marlborough Pharmaceuticals Ltd). MHRA. https://products.mhra.gov.uk/. Accessed 16/09/2020.

Joint Formulary Committee. Nonoxinol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/09/2020.

Nonoxynol-9. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 16/09/2020.

Disclaimer: This information is independently developed by MIMS based on Nonoxinol 9 from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in